The researchers based at the Institute for Comprehensive Medical Science, Fujita Health University, Aichi, Japan, named these brain cells as "Layer 1 Inhibitory Neuron Progenitor cells" (L1-INP).
These cells could potentially pave the way for the treatement of neuro-degenerative diseases and psychiatric disorders, the journal Neuropsychopharmacology reports.
Until now it was not known whether L1-INP-related neurogenesis (production of such brain cells) could be induced in the normal adult cortex (grey matter).
Tsuyoshi Miyakawa, Koji Ohira, and their colleagues employed fluoxetine, one of the most widely used anti-depressants, to stimulate the production of new neurons from L1-INP cells, according to Fujita statement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
